The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism
Open Access
- 20 November 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4), 93
- https://doi.org/10.3390/ijns6040093
Abstract
Glutaric aciduria type 1, homocystinuria, isovaleric acidaemia, long-chain hydroxyacyl CoA dehydrogenase deficiency and maple syrup urine disease are all inborn errors of metabolism that can be detected through newborn bloodspot screening. This evaluation was undertaken in 2013 to provide evidence to the UK National Screening Committee for the cost-effectiveness of including these five conditions in the UK Newborn Bloodspot Screening Programme. A decision-tree model with lifetable estimates of outcomes was built with the model structure and parameterisation informed by a systematic review and expert clinical judgment. A National Health Service/Personal Social Services perspective was used, and lifetime costs and quality-adjusted life years (QALYs) were discounted at 1.5%. Uncertainty in the results was explored using expected value of perfect information analysis methods together with a sensitivity analysis using the screened incidence rate in the UK from 2014 to 2018. The model estimates that screening for all the conditions is more effective and cost saving when compared to not screening for each of the conditions, and the results were robust to the updated incidence rates. The key uncertainties included the sensitivity and specificity of the screening test and the estimated costs and QALYs.Keywords
This publication has 36 references indexed in Scilit:
- Clinical and neurocognitive outcome in symptomatic isovaleric acidemiaOrphanet Journal of Rare Diseases, 2012
- BNF for Children 2009 by Paediatric Formulary CommitteePediatric Critical Care Medicine, 2010
- Economic Evaluation of Tandem Mass Spectrometry Newborn Screening in AustraliaPEDIATRICS, 2009
- The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic ModelValue in Health, 2007
- Natural History, Outcome, and Treatment Efficacy in Children and Adults with Glutaryl-CoA Dehydrogenase DeficiencyPediatric Research, 2006
- Expanding screening for rare metabolic disease in the newborn: An analysis of costs, effect and ethical consequences for decision‐making in FinlandActa Paediatrica, 2005
- A Common Mutation Is Associated with a Mild, Potentially Asymptomatic Phenotype in Patients with Isovaleric Acidemia Diagnosed by Newborn ScreeningAmerican Journal of Human Genetics, 2004
- Screening Newborns for Inborn Errors of Metabolism by Tandem Mass SpectrometryThe New England Journal of Medicine, 2003
- Vascular Outcome in Patients With Homocystinuria due to Cystathionine β-Synthase Deficiency Treated ChronicallyArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Ophthalmic abnormalities in homocystinuria: The value of screeningEye, 1998